Valeant Pharmaceuticals has decided to restructure its operations into three segments. Bausch & Lomb and most of the group's international operations will belong to the durable growth segment, which will represent about half of Valeant's total turnover. The group is also considering the disposal of some core and non-core activities ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.